TARGET CORP

The proposal requests that Target adopt a formal policy requiring the Board Chair to be an independent (non‑executive) director, with limited carveouts for unavailability and without undoing existing contractual obligations. Proponents argue the change would strengthen independent oversight of management and better protect shareholder interests, especially amid recent performance and governance concerns. The filing cites the company’s recent leadership transition (where the outgoing CEO remained as Executive Chair) as a reason for mandating separation of Chair and CEO roles. The proposal asks the Board to amend governance documents as necessary and replace the Chair if the Chair ceases to be independent, subject to the stated exceptions.

The proposal asks Target’s board to publish a report on pesticide presence in the company’s private‑label brands, and to describe oversight, measurement, and reduction efforts, excluding proprietary information. It recommends the report address board oversight, types and quantities of pesticides avoided through targeted strategies, prioritization aligned with authoritative classifications, and any company targets and timelines for reduction. Proponents cite health, environmental, reputational, regulatory, and financial risks — including a cited study finding pesticide residues in Target-branded baby foods — as reasons for increased disclosure and timebound commitments. The request focuses on material issues and urges measurable, risk‑based transparency across the owned‑brand supply chain.

The proposal asks Target to publish an analysis of opportunities to reduce microfiber pollution from its apparel, assessing whether interventions would strengthen long‑term value and mitigate regulatory, reputational, and operational risks. The requested report should evaluate intervention points (mill filtration, fiber/design choices, testing, consumer-facing measures), associated costs and benefits, and whether additional company actions or targets are warranted. Proponents cite scientific evidence of microplastics in the environment and human health concerns, along with regulatory trends (e.g., EU initiatives) and competitor commitments, as drivers of material risk and potential competitive advantage. The report is to exclude proprietary data and focus on material, decision‑useful findings for stakeholders.